April 2025 Vol 18, No 2
By Sara Erickson, PharmD, BCACP; Anna Bartoo, PharmD, BCPS; Amy Wallingford, PharmD; Susan Wescott, MBA, RPh; Chelsee Jensen, PharmD, BCPS, P-RCM, RPh
Biosimilars offer a significant opportunity for cost-savings yet present logistical hurdles for optimal implementation. Biosimilar savings nationwide are estimated to be $54 billion from 2017 to 2026, but these savings hinge on industry, regulatory, and policy changes to strengthen competition and sustainability in the biosimilar marketplace. Read More ›
By Joseph Haroney, PharmD, BCPS; Amanda Kogelman, PharmD, BCOP; Chelsea Palmer, CPhT-Adv, CSPT; Aimee Cloud, PharmD, BCOP; Daniel Kroll, PharmD
Annual US spending on oral cancer drugs has surpassed $947 million and is expected to increase 12% to 15% annually through 2027. In many cases, a significant portion of these funds come directly from patients. The out-of-pocket costs for the top 54 oral chemotherapy agents in 2019 were projected to exceed $10,000 per fill annually for patients enrolled in Medicare Part D plans. Read More ›
By Colleen Hall
A peer navigation model that addresses barriers in clinical trial participation and aims to boost enrollment in childhood cancer therapeutic clinical trials is underway, and one of the study researchers presented on the model at the 66th American Society of Hematology Annual Meeting & Exposition, held recently in San Diego, CA. Read More ›
No one likes to watch their investments lose money, but downward market volatility can feel particularly scary for people who plan to retire in the near future. Their anxiety is understandable. They’ve spent their careers building their nest eggs and now—at a time when they plan to give up their income-producing jobs—they face the prospect of living off less money than they had envisioned.
Read More ›